Tamoxifen's impact on the management of breast cancer: The oncologist's perspective

ONCOLOGY

Volumn 11, Issue 2 SUPPL. 1, 1997, Pages 49-54

  Glick, John H ^a   Aviles, Victor M ^a   Wallmark, John ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CONFERENCE PAPER; FEMALE; HUMAN; MENOPAUSE; METASTASIS; QUALITY OF LIFE; SURVIVAL;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CONSENSUS DEVELOPMENT CONFERENCES, NIH; FEMALE; HUMANS; MEDICAL ONCOLOGY; PATIENT EDUCATION; TAMOXIFEN; UNITED STATES;

EID: 0030900135     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. 1985 NIH Consensus Development Conference Report: Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985.
2. 1990 NIH Consensus Development Conference Statement. Treatment of early stage breast cancer. JAMA 265:391-395, 1991.
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-5, 71-85, 1992.
4. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Instit 88:1529-1542, 1996.
5. Goldhirsch A, Wood WC, Senn HJ et al: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Instit 87:1441-1445, 1995.